Inventor

SETIADY JULIANTO

US12 patents

⚠️ This page may combine multiple inventors who share the name “SETIADY JULIANTO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

IMMUNOGEN INC

6 patents

US10017578B2Jul 10, 2018

Methods of treating cancer in a patient by administering anti-folate-receptor-1 (FOLR1) antibodies

IMMUNOGEN INC12 citations92

US9637547B2May 2, 2017

Monoclonal antibodies for detection of folate receptor 1

IMMUNOGEN INC15 citations92

US10544230B2Jan 28, 2020

Methods of using antibodies to detect folate receptor 1 (FOLR1)

IMMUNOGEN INC4 citations83

US11932701B2Mar 19, 2024

Method for increasing the efficacy of cancer therapy by administering an anti-FOLR1 immunoconjugate

IMMUNOGEN INC1 citations72

US11834498B2Dec 5, 2023

Biparatopic FR-alpha antibodies and immunoconjugates

IMMUNOGEN INC2 citations72

US9125896B2Sep 8, 2015

EGFR-binding molecules and immunoconjugates thereof

IMMUNOGEN INC3 citations62

SETIADY JULIANTO

3 patents

US8790649B2Jul 29, 2014

EGFR-binding molecules and immunoconjugates thereof

SETIADY JULIANTO26 citations90

US9233171B2Jan 12, 2016

Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate

SETIADY JULIANTO4 citations71

US9238690B2Jan 19, 2016

Non-antagonistic EGFR-binding molecules and immunoconjugates thereof

SETIADY JULIANTO1 citations50

DEBIOPHARM INT SA

1 patent

US10556958B2Feb 11, 2020

CD37-binding molecules and immunoconjugates thereof

DEBIOPHARM INT SA7 citations83

DECKERT JUTTA

1 patent

US9447189B2Sep 20, 2016

CD37-binding molecules and immunoconjugates thereof

DECKERT JUTTA13 citations82

IMMNOGEN INC

1 patent

US11396543B2Jul 26, 2022

Biparatopic FR-α antibodies and immunoconjugates

IMMNOGEN INC4 citations67